The potential of adaptive licensing to boost investment
This article was originally published in SRA
Small- and medium-sized drug firms should consider which of their development-stage assets might be candidates for adaptive licensing – a regulatory pathway that is being explored as a means of increasing the efficiency of the development cycle.
You may also be interested in...
Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
UK health technology assessment body NICE says that Medtronic’s Reveal LINQ, which transmits data remotely to doctors, is likely to be a cost-effective use of National Health Service resources.
Using the QALY is expected to help the Danish Medicines Council make its decisions on the cost effectiveness of drugs more transparent, but it will also extend the time the council takes to make a recommendation.
Members of Italian industry body Confindustria Dispositivi Medici should insert a suitable transparency clause in their agreements with health care professionals, says law firm Osborne Clarke, after the trade association introduced a new requirement relating to payments to HPCs.